135 related articles for article (PubMed ID: 21811744)
1. Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection.
Gerna G; Lilleri D; Furione M; Baldanti F
New Microbiol; 2011 Jul; 34(3):229-54. PubMed ID: 21811744
[TBL] [Abstract][Full Text] [Related]
2. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
3. Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients.
Gerna G; Lilleri D; Furione M; Castiglioni B; Meloni F; Rampino T; Agozzino M; Arbustini E
New Microbiol; 2012 Jul; 35(3):279-87. PubMed ID: 22842597
[TBL] [Abstract][Full Text] [Related]
4. Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host.
Lilleri D; Zelini P; Fornara C; Comolli G; Revello MG; Gerna G
Clin Immunol; 2009 Jun; 131(3):395-403. PubMed ID: 19268633
[TBL] [Abstract][Full Text] [Related]
5. Monitoring transplant patients for human cytomegalovirus: Diagnostic update.
Gerna G; Lilleri D
Herpes; 2006 May; 13(1):4-11. PubMed ID: 16732996
[TBL] [Abstract][Full Text] [Related]
6. Monitoring human cytomegalovirus infection in transplant recipients.
Baldanti F; Lilleri D; Gerna G
J Clin Virol; 2008 Mar; 41(3):237-41. PubMed ID: 18203657
[TBL] [Abstract][Full Text] [Related]
7. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients.
Gabanti E; Bruno F; Lilleri D; Fornara C; Zelini P; Cane I; Migotto C; Sarchi E; Furione M; Gerna G
PLoS One; 2014; 9(8):e106044. PubMed ID: 25166270
[TBL] [Abstract][Full Text] [Related]
10. Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation.
Baldanti F; Lilleri D; Gerna G
Hematol Oncol; 2008 Sep; 26(3):123-30. PubMed ID: 18386849
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
[TBL] [Abstract][Full Text] [Related]
13. Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.
Gabanti E; Lilleri D; Ripamonti F; Bruno F; Zelini P; Furione M; Colombo AA; Alessandrino EP; Gerna G
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2192-2202. PubMed ID: 26260678
[TBL] [Abstract][Full Text] [Related]
14. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy.
Brestrich G; Zwinger S; Roemhild A; Noutsias M; Rohde M; Keeren K; Sawitzki B; Volk HD; Reinke P; Hammer MH
J Immunother; 2009; 32(9):932-40. PubMed ID: 19816188
[TBL] [Abstract][Full Text] [Related]
15. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric analysis of virus-specific T lymphocytes: practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation.
Buxbaum S; Kraus FB; Hahn A; Beck O; Kabartas B; Doerr HW; Ludwig B
J Immunol Methods; 2006 Apr; 311(1-2):164-73. PubMed ID: 16530782
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation.
Ludwig B; Kraus FB; Kipp M; Preiser W; Schwerdtfeger R; Doerr HW; Buxbaum S
J Clin Virol; 2006 Feb; 35(2):160-6. PubMed ID: 16112610
[TBL] [Abstract][Full Text] [Related]
18. Saliva as a source of HCMV DNA in allogeneic stem cell transplantation patients.
Correia-Silva JF; Bruna-Romero O; Resende RG; Miranda LP; Oliveira FE; Costa FO; Xavier SG; Figueiredo-Neves SP; Almeida HC; Bittencourt H; Gomez RS
Oral Dis; 2010 Mar; 16(2):210-6. PubMed ID: 20374507
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
20. Human cytomegalovirus-specific CD4(+) and CD8(+) T-cell response determination: comparison of short-term (24h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host.
Zelini P; Lilleri D; Comolli G; Rognoni V; Chiesa A; Fornara C; Locatelli F; Meloni F; Gerna G
Clin Immunol; 2010 Aug; 136(2):269-81. PubMed ID: 20493777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
